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Background: The molecular behavior of biological systems can be described in terms of three fundamental
components: (i) the physical entities, (ii) the interactions among these entities, and (iii) the dynamics of these
entities and interactions. The mechanisms that drive complex disease can be productively viewed in the context of
the perturbations of these components. One challenge in this regard is to identify the pathways altered in specific
diseases. To address this challenge, Gene Set Enrichment Analysis (GSEA) and others have been developed, which
focus on alterations of individual properties of the entities (such as gene expression). However, the dynamics of the
interactions with respect to disease have been less well studied (i.e., properties of components ii and iii).
Results: Here, we present a novel method called Gene Interaction Enrichment and Network Analysis (GIENA) to
identify dysregulated gene interactions, i.e., pairs of genes whose relationships differ between disease and control.
Four functions are defined to model the biologically relevant gene interactions of cooperation (sum of mRNA
expression), competition (difference between mRNA expression), redundancy (maximum of expression), or
dependency (minimum of expression) among the expression levels. The proposed framework identifies
dysregulated interactions and pathways enriched in dysregulated interactions; points out interactions that are
perturbed across pathways; and moreover, based on the biological annotation of each type of dysregulated
interaction gives clues about the regulatory logic governing the systems level perturbation. We demonstrated the
potential of GIENA using published datasets related to cancer.
Conclusions: We showed that GIENA identifies dysregulated pathways that are missed by traditional enrichment
methods based on the individual gene properties and that use of traditional methods combined with GIENA
provides coverage of the largest number of relevant pathways. In addition, using the interactions detected by
GIENA, specific gene networks both within and across pathways associated with the relevant phenotypes are
constructed and analyzed.
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Genome-wide mRNA expression data provide a rich re-
source for studying the molecular mechanisms of com-
plex diseases. Through comparison of mRNA expression
data between case and control samples, biomarkers and
functional molecules significant for diagnosis, prognosis,
and treatment have been identified for many complex
diseases, including cancers [1,2]. Extracting signals while* Correspondence: yxl442@case.edu
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reproduction in any medium, provided the orrejecting noise in the data and interpreting the results to
elucidate biological mechanisms relevant to disease are
however, challenging [3]. Lists of hundreds of mRNAs
identified as differentially expressed are interesting but
can be difficult to interpret in terms of the complex
underlying biological processes. In addition, there are in
many cases limited overlap between lists of individually
dysregulated genes identified by different laboratories
that study the same disease [3,4]. To overcome these
challenges, a number of methods that consider genes
not as individual entities but as members of biological
relevant groups have been developed. Among suchis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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very powerful and highly popular.
While being quite useful for system-level analyses,
GSEA and similar methods, such as gene set analysis
(GSA, [5]) have a limitation: they focus only on the mole-
cules (i.e., genes) that comprise a pathway and may neg-
lect the changing interactions among genes within a
pathway. Consequently, only pathways enriched in indi-
vidual differentially expressed genes are detected with stat-
istical significance. However, gene interactions and the
dynamics of these interactions are also essential compo-
nents of pathways and they underlie the orchestration of
biological processes at many levels [6]. Interactions are
associated with several dynamic characteristics, such as
their direction, strength, permanence or transience, and
presence or absence [6]. The biological influence of a
pathway can be dramatically changed if the dynamics of
the interactions in the pathway are altered. Indeed, several
studies have demonstrated that the changes in the dynam-
ics of interaction are associated with cancer and other dis-
eases [7-9].
In this vein, Zhang et al. have proposed a method in
which the interactions were represented by the co-
variances or correlations between case and control classes,
and showed that this approach provides biologically
meaningful results [8]. Eddy et al. developed another
method called DIfferential RAnk Conservation (DIRAC),
which is based on the relative expression ranks of genes in
a pathway [10,11]. A limitation of this method, however, is
that it assesses the change in the relationship between
genes qualitatively, and misses cases in which (i) changes
in expression are not large enough to change the relative
order of genes or (ii) the difference between the expres-
sions levels becomes even larger. Watkinson et al. defined
the synergy among pairs of genes in terms of the mutual
information between phenotype and the clustering of
samples induced by the gene expression levels [12] and
extracted disease-specific interactions in cancer. Another
class of algorithms for system-level analysis of differential
gene expression aims to identify dysregulated subnetworks
in disease [2]. Using protein-protein interaction (PPI) net-
works as a template for assessing functional associations
among genes, these methods identify groups of function-
ally related genes that exhibit collective mRNA-level dif-
ferential expression with respect to disease based on:
mutual information, cover-based algorithms and others
[13,14]. These results strongly suggest that dysregulation
of interactions is as important a mechanism of disease as
dysregulation of genes.
In order to further explore the dysregulation of gene
interactions in disease, we have developed Gene Inter-
action Enrichment and Network Analysis (GIENA), which
implements four mathematically simple, yet powerful
interaction profile functions to model gene interactions.The hypothesis behind the analysis, suggested by the work
described above, is that dysregulation of interactions, like
the dysregulation of individual genes revealed by GSA, is
an important set of variables to analyze to provide a com-
prehensive understanding of mechanisms of disease.
GIENA attempts to provide a set of interaction profiles
that are associated with universal biological concepts. We
then use the canonical pathway information to drive a
specific network analysis to indentify hub genes that may
mediate communication across pathways. These profiles
and their biological interpretation are as follows: (i) the
sum of mRNA expression levels, which models cooper-
ation, (ii) the difference between mRNA expression levels
models competition, (iii) the maximum mRNA expression
level models redundancy, and (iv) the minimum mRNA
expression level models dependency between a pair of
genes. This framework provides a basis for interrogating
both the dynamics of multiple types of interactions and
gives clues to the regulatory logic of the perturbed net-
works, both within pathways and across pathways, as
opposed to simply identifying the dysregulated players.
We evaluated these four interaction profiles using previ-
ously published mRNA expression datasets associated
with cancer [15-19]. We detected multiple disease-
associated gene interactions, which we annotated with
their biological significance and compared to known lit-
erature findings to validate the results. Also, we used the
approach to compare data from different experimental
studies to examine the robustness of the method. Then,
we constructed gene interaction networks based on these
detected interactions and analyzed the results as well, in
this case to better understand potential novel connections
between pathways and to provide testable hypothesis for
future experimental validations. Our results show that
GIENA is able to reliably detect both known and novel
dysregulated canonical pathways and dysregulated inter-
action networks related to the disease. In addition, the
method gives consistent results across datasets from dis-
parate laboratories. Overall, GIENA is systematic ap-
proach for the identification of dysregulated interactions
at the pathway level and provides specific guidance for in-
terpretation of disease-specific interactions in complex
diseases.
Methods
Models of gene interactions in GIENA
Four functions, named interaction profiles, are implemen-
ted to uncover different biological mechanisms that
underlie the coordinated differential expression of the
genes. G= {g1, g2,. . ., gn} denotes the set of genes for which
mRNA expression data is available, S= {s1, s2,. . ., sm}
denotes the set of samples, and cj denotes the phenotype
of sample sj. The normalized mRNA expression profile
of gene gi, is denoted by m-dimensional vector ei such that
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the number of samples).
Cooperation (sum of expression)
Genes often cooperate with each other to perform vari-
ous cellular functions and are organized into functional
modules with densely connected genes within modules
and a small number of interactions between modules
[20]. Comparing the total expression across samples of
interest can reveal disruptions in cooperative function.
Indeed, Chuang et al. infer the activity of a subnetwork
by averaging the normalized expression values of its
member genes and identify dysregulated subnetworks in
terms of the mutual information between this average
expression and phenotype [13]. In our study, in order to
systematically assess pairwise gene interactions, we use
this concept in its simplest form: for each pair of genes,
the sum of their mRNA expression levels is compared
between disease and control samples to detect cooper-
ation interactions dysregulated in diseases. Thus, we de-
fine the cooperation profile for genes gi and gj as
tij kð Þ ¼ ei kð Þ þ ej kð Þ for 1≤k≤m ð1Þ
and quantify the strength of cooperative interaction be-
tween gi and gj in terms of the statistical significance of
the difference of tij in disease and control samples.
Competition (difference in expression)
If two genes are working together to balance each other’s
effects, assuming that their activities are correlated with
mRNA expression, we can expect the difference between
their mRNA expression levels to represent the regulatory
balance between them. An example would include two
transcription factors (TF) that act on a set of targets, but
in opposite directions, i.e. one inhibits activity of the tar-
get promoter site while the other enhances activity. Con-
sequently, changes in expression levels of these two TFs
will result in maximal dysregulation of their targets
when their abundance levels vary in opposite directions
while their effects may be minimal when their abun-
dance levels vary in the same direction. Motivated by
these considerations, we define the competition profile of
genes gi and gj, as
dij kð Þ ¼ ei kð Þ  ej kð Þ for 1≤k≤m ð2Þ
and quantify the strength of competitive interaction be-
tween gi and gj.
Such comparisons of differences in mRNA expression
levels have been used in disease classification. For ex-
ample, the relative expression difference of OBSCN and
C9orf65 can distinguish two phenotypically similar can-
cers with high accuracy although the underlying biology
is still unclear [21]. This method has been applied toconstruct gene regulatory networks and develop prog-
nostic test for cancer [22,23]. Furthermore, Taylor et al.
used difference in mRNA expression of the central hub
gene in a subnetwork with its interacting partners to as-
sess changes in the coherence of the subnetwork [24].
Redundancy (maximum expression) and Dependency
(minimum expression)
Besides collectively working together, genes can cooper-
ate in other ways, one example would be the wide-
spread genetic interactions detected in yeast (deleting ei-
ther of two genes has no obvious effect, removing both
will have lethal effect [9]). For such pairs of genes, the
suppression of both or over-expression of only one can
be sufficient for dysfunction. To quantify its strength
and detect gene interaction dysregulation in disease, we
use the maximum mRNA expression for pairs of genes
to define the redundancy profile of genes gi and gj as
hij kð Þ ¼ max ei kð Þ; ej kð Þ
 
for 1≤k≤m ð3Þ
In cases which two genes are required for a common
function, suppression of one of them or over-expression
of both may lead to dysfunction. To identify such interac-
tions, we use the minimum mRNA expression for pairs of
genes to define the dependency profile of genes gi and gj as
lij kð Þ ¼ min ei kð Þ; ej kð Þ
 
for 1≤k≤m ð4Þ
These four gene interaction profiles are conceptually
illustrated in Figure 1.
Overview of GIENA
Using the four profiles described above for each pair of
genes, we identify gene sets (pathways) that are enriched
in dysregulated gene interactions, i.e., pathways in which
these profiles are significantly altered between disease and
control samples for a large number of gene pairs in the
pathway. For this purpose, we use the comprehensive
pathway data downloaded from the Molecular Signatures
Database (MSigDB) (http://www.broadinstitute.org/gsea/
msigdb). We focus on the dataset that represents canon-
ical representations of 633 biological processes compiled
by domain experts (c2.cp, version2.5). Note that the genes
in a pathway in MSigDB do not necessarily interact phys-
ically with each other; thus the interactions identified here
are not to be confused with physical interactions and they
should be considered as higher level “relationships”.
In order to identify the dysregulated pathways, GIENA
uses the framework of GSA which generalizes the original
GSEA [5]. For a pathway P with set of genes g1, g2, . . ., gk,
the overall procedure is summarized as follows:
1) For each pair of gi and gj in P, the cooperation
profile tij, competition profile dij, redundancy profile
Figure 1 Illustration of four genetic interaction profiles. Note that in each case, the change of individual gene expression might not be
statistically significant, but the change of the interaction profile could become statistically significant between case and control samples. A:
cooperation profile. B: competition profile. C: redundancy profile. D: dependency profile.
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disease and control groups separately. These four
profiles are used to detect dysregulated pathways
independently. In the following, we use the
cooperation profile tij as an example to explain the
procedure for detecting dysregulated pathways.
2) The classic two-sample t-statistic (Zij) is calculated
as the standardized difference of tij between disease
and control groups. Repeating this procedure for
each pair of genes in the pathway, a set of summary
statistics Z(P)= {Z12 Z13 . . . Z1k Z23 Z24. . . Z2k . . .
Zk-1,k} is obtained for each pair of genes in the
pathway. Note that, no hypothesis testing is done at
this point; these statistics are only used to score the
pathways.3) The “maxmean” statistic S(P) for the pathway is
computed to summarize Z(P). The maxmean statistic
is designed to detect unusually large z-values in either
or both directions [5]. Namely, given the vector Z(P),
the "maxmean" statistic is the mean of the positive or
negative part of gene-pair scores in the pathway,
whichever is larger in absolute value, i.e.:








Pð ÞZij= Z Pð Þj j
n o
ð5Þ
where Z+(P)= {Zij 2 Z(P): Zij> 0} and Z-(P)= {Zij 2 Z
(P): Zij< 0}. It was shown previously that this statistic
is more powerful than the modified Kolmogorov-
Smirnov statistic used in the original GSEA [5].
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deviation of tij as in GSA. For details and the
theoretical underpinnings of this procedure, please
refer to [5].
5) The significance of S(P) is then evaluated using a
permutation test. Namely, the data columns (sample
labels) are permuted to generate a randomized
dataset and this dataset is used to re-compute S’.
Repeating this procedure for a sufficiently large
number of times (B = 5000 permutations are
performed in our experiments), a null distribution of
standardized maxmean statistics S’1, S’2, . . ., S’B, is
obtained. Using this distribution, the p-value for
pathway P is estimated as the number of permuted
datasets that yield a larger standardized maxmean
statistic than the original dataset on P, i.e., p-value
(P) = |{1 ≤ i ≤B: S’i(P) ≥ S(P)}|/B.
6) Due to the stochastic nature of permutation test,
p-values from each run will be slightly different
(each single run has 5000 permutations). Thus, the
permutation is repeated at least four times for each
profile, and the average of the p-values is used.
7) In order to correct for multiple hypothesis testing in
the procedure to detect dysregulated pathways, the
q-value is calculated using the Q-value package [25].
Pathways with q-value ≤ 0.01 are considered
significantly dysregulated.
Similarly, the above procedure is repeated for other
interaction profiles, and enriched pathways are identified
for each profile separately.
Network construction
To construct the network enriched with dysregulated
interactions, for each dyregulated pathway identified,
each gene pairs are tested for dysregulation using classic
t-test. To avoid the network with sparse and highly sig-
nificant connections, a loose p-value threshold (0.05)
without correction of multiple testing is applied.
Gene expression data sets
P53 mutant data set
The National Cancer Institute (NCI) has collected a set of
human cancer cell lines (NCI-60) derived from diverse tis-
sues, like brain, blood, breast, and colon, etc. These cell
lines have been subjected to various experiments includ-
ing genotyping and gene expression analysis. Conse-
quently, a wealth of genomic and validation data is
available for the well-known tumor suppressor gene p53,
which regulates the expression of a large number of genes
in response to various signals of cellular stress and is often
mutated in human cancers. For 50 of the NCI-60 cell
lines, the p53 mutational status has been tested, and 17
are identified as wild type while the rest are mutant [15].For these cell lines, the mRNA expression levels of 10,100
genes are also available [26] and downloaded from http://
www.broadinstitute.org/gsea/data sets.jsp. In this study,
these 50 cell lines are divided into two classes based on
the status of p53 (wild type vs mutant), and GIENA and
GSA methods are applied to detect pathways enriched in
differential interactions and genes between two classes
using the mRNA expression data.
Pancreatic cancer data set
Pancreatic cancer is often diagnosed at advanced stages.
As a consequence, very few patients survive longer than
five years after diagnosis. Ishikawa et al. compared the
gene expression profiles of 24 pancreatic cancer patients
and 25 healthy individuals to identify novel disease path-
ways [16]. We used this dataset (GSE1542) to identify
the dysregulated pathways in pancreatic cancer.
Breast cancer datasets
GSA and GIENA were applied on three microarray data-
sets from previous studies to detect pathways associated
with breast cancer staging and prognosis [17-19]. The
datasets (GSE7390, GSE19615 and GSE26639) were
divided into three groups based on the histological grad-
ing, and grades I and III were used for pathways detection.
There are 30 grade I and 82 grade III tumors in GSE7390;
23 grade I and 64 grade III tumors in GSE19615 and
GSE26639 contains 15 grade I and 121 grade III tumors.
To make the latter dataset more balanced, 30 grade III
tumors were randomly selected to compare with the 15
grade I tumors. GSA and GIENA were applied for each
pair of grade I and III tumors respectively. The results
from three datasets were compared to examine the repro-
ducibility of the methods.
Microarray data processing
Software Expander was used to process the microarray
data [27]. The robust multichip average (RMA) and quan-
tile normalization method were applied to normalize the
data, and the expressions of multiple probesets are sum-
marized to the expression of corresponding genes using
Expander, then GIENA and traditional GAS were used to
detect dysregulated pathways.
Statistical testing of the overlap between physical and
dysregulated interactions
In order to investigate the physical bases of the dysregu-
lated interactions identified by GIENA, we compared
these interactions with PPIs downloaded from a com-
monly used database Human Protein Reference Data-
base, or HPRD. For each of the datasets used (p53, breast
cancer, pancreatic cancer datasets), we separately identi-
fied the pairs of genes that (i) exhibit significantly dysre-
gulated interactions and (ii) interact in the HPRD PPI
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overlap using hypergeometric test.
To be more precise, assume that r pathways are tested
for a given dataset. For 1≤ i ≤ r, let ci denote the number
of pairs of genes in pathway i such that both genes in
the pair has at least one interaction in HPRD. We use
the following parameters for the hypergeometric test:
 N ¼Pri¼1ci: the number of gene pairs that are tested
for dysregulated interaction and can potentially have a
physical interaction (population size).
 n: the total number of significantly dysregulated
interactions for the dataset of interest (sample size).
 m: the number of interactions in HPRD among
proteins that together take part in at least one of the
tested pathways, i.e., that have been tested for
dysregulated interaction (total number of successes).
k: The number of gene pairs with a significantly dysre-
gulated interactions and a physical interaction in HPRD
(number of successes in the sample).
Once N, n, m, and k are obtained we compute the
p-value of this observation as












i.e., the probability that there would be at least k physical
interactions among significantly dysregulated gene pairs
if the dysregulated interactions were chosen at random.Table 1 Q-values for pathways detected by of GIENA and GSA
Pathway Cooperation Competition
P53 0.005 0.004
P53 hypoxia 0.016 0.004







FAS signaling 0.016 0.005
ALS 0.043 0.008
RACCYCD 0.043 0.008
Programmed cell death 0.016 0.009
FML 0.045 0.05
HSP27 0.016 0.011
q-value< 0.01 is considered as significant, and highlighted in bold.Here, X denotes the random variable that represents the
overlap between the two sets of interactions. Note that
we do not correct for multiple hypotheses since only one
such test is performed for each dataset.
Gene interaction network construction
Detected gene interactions are used to construct net-
works. These networks represent parts of the interactome
which are disrupted in complex diseases. For each dysre-
gulated pathway, interactions identified (with p-value
<0.05) are collected. The network is generated and visua-
lized using Cytoscape.
Results and discussion
GIENA reveals pathways and network dysregulated with
respect to p53 status in NCI-60 cell lines
Enrichment results from GIENA and GSA for the p53
status data are shown in Table 1. GSA detects six path-
ways with q-values< 0.01. Two of them (p53 and p53
hypoxia) are directly linked to p53. Others have obvious
links to tumorigenesis, such as the RAS pathway [28],
which is also well understood to be related to p53 ex-
pression regulation [17]. The significant G1 & S phase
pathway contains members that regulate the progression
through G1-S phases of the cell cycle, such as CDK2
and CDK4 [29]. In the case of DNA damage, p53 accu-
mulates in the cell and induces the inhibition of CDK
[29]. This pathway also includes TP53, the protein prod-
uct of p53, MDM2, the master regulator of p53 [30], and
E2F, which regulates p53 indirectly [31].
GIENA detects over twice as many pathways at q-
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detected by GSA, with four of the pathways, such as
p53, p53 hypoxia, G1 & S phase and RAS, detected by
both using the above q-value cutoff. These results sug-
gest that mutations in p53 have profound affects at both
individual gene and gene-gene interaction levels and that
some of the pathways are primarily perturbed at the
level of individual genes (seen by GSA alone), some are
perturbed in both individual genes and in their interac-
tions (intersecting pathways) and some are perturbed
primarily at the level of interactions (seen by GIENA
alone). Several pathways identified using GIENA alone
are entirely confirmed by an examination of the litera-
ture. For example, the mitochondria pathway (role of
mitochondria in apoptotic signaling), BAD (Regulation
pathway of BAD phosphorylation), and FAS pathways
[32-34] are all linked to apoptosis and highly relevant to
p53 functions [35]. The BAD pathway is ranked rela-
tively highly in the results from GSA, (eighth ranked
pathway with q around 0.02), while it is assigned 5-fold
more significant q-values by GIENA (0.004) based on
the competition profile. BAD exhibits dysregulation at
the level of both the individual gene and at the level of
gene interactions and GIENA can pinpoint relevant
regulatory logic of the pathway that is potentiallyFigure 2 Network for P53 dataset using GIENA. Network generated usin
dataset after filtering the significantly differentially expressed genes betwee
indicate that physical interactions between the products of the respective
interactions; purple lines represent dependency interactions; orange lines r
interactions were detected by multiple interaction profiles. Note that there
unique pathway is detected by cooperation profile.perturbed (see below). Specifically, these observations
provide a testable hypothesis that a subset of competing
interactions within the BAD pathway is critical to the
changes seen as a result of p53 status.
In order to leverages the pathway results to uncover
potential interesting interactions across pathways, we
constructed a network of dysregulated interactions in
which the edges represent dysregulated interactions
from any of the four profiles. To simplify the network
and focus on the novel findings from GIENA, genes that
are significantly differentially expressed between cases
and controls at q-values< 0.01, (in total three genes
BAX, MDM2, and CDKN1A) are removed. Also, the 17
genes that did not have any significantly dysregulated
interactions with the remaining nodes were also deleted.
The sub-network after filtering is shown in Figure 2,
which has 95 nodes with 186 interactions derived from
six pathways and is organized to show the underlying
relevant pathways based on data from MSigDB. The net-
work in Figure 2 illustrates several typical characteristics
of biological networks, such as the existence of hubs.
There are hubs clearly located within pathway gene sets
(e.g. FAS in FAS induced apoptosis and BCL2 in the
mitochondrial pathway) as well as hubs connecting mul-
tiple pathways. For example, TP53 (the protein productg the dysregulated interactions identified by GIENA on the P53
n cases and controls, and the resulting singletons. The dashed lines
genes are reported in HPRD. The green lines represent competition
epresent redundancy interactions. The blue lines indicate that these
is no cooperation interaction presented in this network, because no
Figure 3 Simplified BAD pathway. Solid lines represent gene
interactions detected by competition profiles using mRNA
expression. Dashed lines indicate the physical interactions. The
numbers beneath the gene names are p-values corresponding to
the expression change between mutant p53 and wild type p53
samples. The numbers above lines are p-values for the change in
the competition profile for two genes connected between mutant
p53 and wild type p53 samples. The arrows inside the gene symbols
indicate the trends of the mRNA expression of mutant p53 samples
in respect to p53 wild type samples, though the change is not
statistically significant.
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dependent kinase 2) exhibit significantly dysregulated
interactions across at least three pathways. Although
TP53 and CDK2 are not hubs within any particular
pathway set, they directly link three and four dysregu-
lated pathways, respectively. Nodes that connect more
than one major regulatory module (pathway) we term
"cross pathway" hubs. Interestingly some hubs exhibit
only moderate differential expression between case and
control (e.g., CFL1 has q-value: 0.03; FAS, 0.13; and
PIK3CA, 0.14), i.e., the dysregulation of these individual
genes is not captured by methods that are based on dif-
ferential expression of individual genes alone. However,
the interactions of these genes with other genes are dis-
rupted in the phenotype, which is detected by GIENA.
Cofilin 1 is an important regulator of the actin cytoskel-
eton and thus is a critical regulator of cell motility while
CDK2 functions to signal the G1/S cell cycle transition.
The GINEA analysis indicates that changes in the inter-
action of these proteins are important to the phenotypic
differences relevant to p53 status. Overall, both within
pathway hubs and cross pathway hubs are interesting
candidates for experimental perturbation by knockdown
or knockout, such experiments could define the relation-
ship of the hub to overall phenotype and test the import-
ance of the detected interactions. This is a stated
purpose of the tool, to identify specific points of per-
turbation within pathways for experimental testing.
Regulatory logic of BAD pathway probed by GIENA
In an attempt to explore the biological significance of the
network connections suggested by GIENA, we examined
the details of the regulation of BAD pathway. Figure 3
shows a simplified BAD pathway that includes: two genes
that show dysregulation with respect to individual gene
expression in the p53 datasets (e.g. BAX and PIK3CA),
three pairs of genes that show dysregulated interactions
(CSF2RB-IL3RA, IL3RA-PRKACG, and PRKACG-
PRKAR2A), and additional genes that connect them with
BAD as the hub.
The dysregulation of the genes BAX and PIK3CA pro-
vided a q-value of 0.02 in the GSA based analysis of this
pathway while the competition profile from GIENA gen-
erated greater significance with a q-value of 0.004
(Table 1). Thus, an examination of interactions provides
greater confidence in establishing dysregulation of this
pathway than examining dysregulated genes alone. In
examining the individual gene p-values, we can see that
neither CSF2RB, IL3RA, PRKACG, nor PRKAR2A are
dysregulated at the individual gene level, their interactions
that show significant changes between phenotype and
control (Figure 3). Detailed inspection of the expression
patterns of these genes shows that CSF2RB is slightly (but
not significantly, p-value 0.08) down regulated in case vs.control while IL3RA is slightly up-regulated (but not sig-
nificantly, p-value 0.26). IL3RA gene encodes the interleu-
kin 3 specific ligand binding subunit of a receptor hetero-
dimer complex where the signaling domain is shared
among and responds to multiple ligands, including colony
stimulating factor 2. Thus, we suggest that the reciprocal
expression changes in the CSF2RB-IL3RA pair provide a
finely tuned system for maintaining molecular balance in
downstream signaling to PI3K, and subsequently to AKT1
and BAD, which can provide tight control for apoptosis
signaling overall. This concept of molecular balance has
been previously elaborated for PI3K signaling [36]. Note
that the competition profile also reveals potential regula-
tion by molecular balance in the PRKACG-PRKAR2A
(cyclic AMP dependent protein kinase gamma catalytic
subunit and type-II alpha regulatory subunit) ligand-
receptor interactions as well. Thus, the use of the compe-
tition profile revealed sub-components of the BAD path-
way that are involved in maintaining tight molecular
balance of signaling, changes that could not be detected
by individual gene expression alone.
GIENA discovers dysregulated pathways and networks in
pancreatic cancer
Enrichment results from GSA and GIENA for the pancre-
atic cancer data are shown on Table 2. GSA does not detect
any pathway with a significant q-value. In comparison,
Table 2 Q-values of pathways detected by GIENA for the pancreatic cancer dataset
Pathway Cooperation Competition Redundancy Dependency GSA
Glycosphingolipid biosynthesis 0.018 0.002 0.004 0.027 0.064
Classic complement activation 0.047 0.003 0.040 0.027 0.052
Classic 0.047 0.003 0.034 0.027 0.064
Classic & alternative complement 0.047 0.004 0.039 0.026 0.052
ACE2 0.047 0.004 0.027 0.026 0.064
Bisphenol A degradation 0.049 0.009 0.048 0.027 0.064
Lysine degradation 0.037 0.009 0.040 0.028 0.061
Renin-angiotensin system 0.047 0.009 0.035 0.027 0.052
Glycosphingolipid biosynthesis (neo-lactoseries) 0.018 0.026 0.004 0.027 0.064
q-value< 0.01 is considered as significant, and highlighted in bold. Note none of pathways has significant q-value using GSA.
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http://www.biomedcentral.com/1752-0509/6/65GIENA detects nine pathways, including glycosphingolipid
biosynthesis, ACE2 (angiotensin-converting enzyme 2), and
several complement pathways. Some of these pathways
were previously shown to be related to cancer but not
much is known about them in pancreatic cancer. Comple-
ment pathways are related to cell killing, recent studies
have shown that an activated complement pathway can kill
tumor cells [37], thus, its association with pancreatic cancer
is logical. The angiotensin converting enzyme precursor 2
(ACE2) pathway is top ranked with a q-value 0.004;
ACE2 protein is a component of the renin-angiotensin-
aldosterone system (RAAS), which regulates blood pressureFigure 4 Network generated using the dysregulated interactions iden
genes were identified as differentially expressed between pancreatic cance
between the products of the respective genes are reported in HPRD. See F
detected by Jones et al. are marked by a star [40].and water (fluid) balance. Recent studies show that ACE2 is
down-regulated in some cancers [38]. In terms of other sig-
nificant pathways accumulation of glycosphingolipid has
been observed in cancer cells [39] and it has been shown
that activated complement pathways can kill tumor cells
[37]. These results suggest that the alterations in the ex-
pression of single genes are often subtle in pancreatic can-
cer and these pathway alterations can be captured only
when interactions are considered.
The network generated using the dysregulated interac-
tions detected by GIENA on the pancreatic cancer dataset
is shown in Figure 4. Note that there is no significantlytified by GIENA on the pancreatic cancer dataset. Note that no
r and normal cells. The dashed lines indicate that physical interactions
igure 2 legend for color coding of interactions. The mutated genes
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http://www.biomedcentral.com/1752-0509/6/65differentially expressed gene (0.01 q-value level). The net-
work has five separate pathways without identification of
cross pathway hubs involved across the disparate pathways.
It may be that multiple unlinked pathways are dysregulated
in pancreatic cancer or that important cross pathways hubs
proteins are as yet unidentified due to limited coverage in
interaction databases. However, within the five pathways
several hub genes are identified, such as, fucosyl transferase
3 (FUT3), Procollagen-lysine 2-oxoglutarate 5-dioxygenase
3 (PLOD3), paraoxanase 3 (PON3) and ACE2 and these
are interesting targets for further experimental investiga-
tion in the disease.
To confirm the GIENA findings, the results are com-
pared with that of Jones, et al., which identified genes
mutated in pancreatic cancer by genome-wide protein-
coding-gene sequencing of 24 patients [40]. Comparison of
this data to our pancreatic cancer networks shows that the
dysregulated networks identified by GIENA contain 12
mutated genes, and each network has at least one mutated
gene (Figure 4, mutated genes are marked with a star).
In particular, five mutated genes are present in the lysine
degradation network including: two aldehyde dehydro-
genases (ALDH1A3 and ALDH3A1), DOT1-like histone
H3 methyltransferase (DOT1L), euchromatic histone-
lysine N-methyltransferase 1 (EHMT1), and serine dehy-
dratase (SDS). More interestingly, although there is no evi-
dence of physical interaction between them in HPRD
(Human Protein Reference Database), GIENA suggests
that SDS interacts with ALDH1A3, ALDH3A1 and
DOT1L (Figure 4). Thus, the pathways detected by GIENA
are supported by recent mutation data. In addition, the epi-
static effects of the mutations are predicted by the GINEA
framework.Table 3 Q-values of pathways detected by GIENA for three br
Pathways Cooperation Competition
Dataset 1 Dataset 2 Dataset 3 Dataset 1 Dataset 2 Data
P27 0.027 0.021 0.0073 0.019 0.025 0.016
FBW7 0.018 0.021 0.0071 0.019 0.028 0.016
PTC1 0.018 0.0073 0.010 <0.0001 0.0013 0.01
Cell cycle 0.018 0.018 0.010 0.0082 0.021 0.014
SRCRPTP 0.0021 <0.0001 0.0063 0.0022 0.0074 0.01
G2 &M phase 0.0095 0.0056 0.010 0.0015 0.0033 0.01
Cyclin 0.018 0.015 0.010 0.0017 0.021 0.016
RB 0.0095 0.0078 0.0071 0.0081 0.0092 0.01
G2 0.0021 0.0056 0.010 0.0082 0.016 0.016
SKP2E2F 0.015 0.018 0.0071 0.019 0.029 0.016
CDC25 0.0035 0.0033 0.0073 0.0082 0.016 0.016
q-value< 0.01 is considered as significant, and q-values for pathways with significan
Two pathways detected by GIENA only are in italics.
Dataset 1: GSE7390; Dataset 2: GSE19615; Dataset 3: GSE26639.
Only pathways detected by at least two datasets listed.
Both P27 and FBW7 pathways are in top 25 pathways in normal GSA results in all tPathways associated with breast cancer prognosis are
consistent across datasets
Breast cancer prognosis is largely driven by the assess-
ment of key clinical characteristics, such as tubule for-
mation, mitotic rate, and nuclear pleomorphism [41];
these are generally combined in a clinical grade. This ap-
proach has become a widely used strategy in the asses-
sing risk of disease relapse and estimating the benefit of
a treatment strategy. More recently, genomic profiling
combined with clinical information was used to refine
prognosis and improve therapeutic strategies for breast
cancer [42]. As outlined in the methods section, we have
identified gene expression data sets nominally associated
with stages I and III. To identify pathways that vary be-
tween the relevant stages, GSA and GIENA were applied
to three previously published datasets [17-19]. GIENA
detected 11 pathways with significant q-values in at least
two datasets (Table 3). Most are clearly associated with
tumorigenesis and development including changes in
interactions of SRC (oncogene) and RB (suppressor)
pathways. Overall, more than half of the detected path-
ways are related to cell cycle (such as cell cycle, P27,
Cyclin, CDC25, G2 and M phase transition, and G2
pathways) and are significantly dysregulated for grades I
vs. III. Of these 11 pathways all but two were detected
by GSA (Table 4). The two pathways missed by GSA are
FBW7 and P27 pathways, FBW7 is a well-known tumor
suppressor and P27 is associated with breast tumor
prognosis [43,44]. Moreover, both pathways are ranked
in top 25 pathways of GSA results for all three datasets,
but with q-values below the threshold, and all pathways
detected by GSA are also detected by GIENA. These
results suggest that in breast cancer most pathways areeast cancer datasets
Redundancy Dependency
set 3 Dataset 1 Dataset 2 Dataset 3 Dataset 1 Dataset 2 Dataset 3
0.023 0.038 0.019 0.014 0.010 0.0062
0.021 0.030 0.019 0.0062 0.020 0.010
4 0.012 0.013 0.019 0.0097 0.015 0.025
0.021 0.032 0.019 0.0043 0.0020 0.017
6 0.0018 0.002 0.0036 <0.0001 0.0010 0.012
4 0.014 0.020 0.019 0.0017 0.0010 0.017
0.021 0.029 0.018 0.0021 0.0010 0.010
6 0.014 0.020 0.018 0.0017 0.0023 0.017
0.0018 0.013 0.019 0.0014 0.0023 0.020
0.019 0.025 0.018 0.0043 0.015 0.0086
0.0093 0.013 0.018 <0.0001 0.0010 0.017
t q-values for at least two datasets are highlighted in bold.
hree datasets.
Table 4 Q-values of pathways detected by GSA for the
three breast cancer datasets
Dataset 1 Dataset 2 Dataset 3
PTC1 0.0077 0.0072 0.013
Cell cycle <0.0001 0.00027 0.0072
SRCRPTP 0.0020 0.0027 0.0043
G2 &M phase 0.0048 0.0025 0.0075
Cyclin 0.019 0.0072 0.0050
RB 0.0048 0.0030 0.0072
G2 0.0020 0.00027 0.011
SKP2E2F 0.0069 0.012 0.0070
CDC25 0.0022 0.00027 0.0075
q-value< 0.01 is considered as significant.
Only pathways detected by at least two datasets are listed.
Dataset 1: GSE7390; Dataset 2: GSE19615; Dataset 3: GSE26639.
Figure 5 Venn diagram of comparison of detected gene
interactions. To test the reproducibility of GIENA, the detected
interactions for P27 pathway are pair-wisely compared for three
breast cancer datasets. Majority of the interactions are detected in all
three datasets. Especially, more than 90% of interactions are shared
between GSE19615 and GSE7390.
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http://www.biomedcentral.com/1752-0509/6/65dysregulated at both the individual gene and at the level
of interaction.
Microarray data are often noisy, and consequently, the
reproducibility often is low across datasets from different
laboratories for the same disease. We further examined
the consistency of the pathways detected by GIENA
across three datasets. In total, 22 pathways are assigned
significant q-values for at least one dataset (data not
shown) and 11 of 22 are significant for at least two data-
sets (Table 3), while the others are often ranked in the
top 50 pathways. We also examined the consistency of
gene interactions detected by GIENA. For P27 pathway
identified by GIENA only, we investigated the overlap of
gene interactions among three datasets. Results show
that 65-83% interactions are shared among all three
datasets (Figure 5), and a pairwise comparison between
GSE7396 and GSE19615 shows even higher overlap;
more than 92% of interactions are shared. Similar over-
lap is observed for FBW7 pathway, which is also
detected by GIENA, but not GSA. It should be noted
that results from dataset GSE26639 is most dissimilar
from the other two, possibly due to its small sample size
(it has the smallest number of grade I patients). In sum-
mary, GIENA results are robust and consistent across
different datasets in identification of both gene interac-
tions and pathways and provide results consistent with
the literature.
Comparison of interaction profiles detected in different
pathways
In order to investigate the biological relevance of the
four proposed interaction profiles (cooperation, competi-
tion, redundancy and dependency), we compared enrich-
ment results for the four profiles. The comparison
shows that the detected pathways are different among
most of the four profiles in many cases (the exception is
cooperation and redundancy, see below), which mightreflect the various underlying biological processes of
complex diseases, e.g., in some conditions the genes
compete to influence phenotype; in others, cooperation
might drive dysregulation.
Pathways detected by cooperation (sum) and redun-
dancy (higher) profiles are similar in the results from the
p53 dataset, e.g. the p53, ABSCELL, and programmed
cell death pathways are identified by both approaches. In
fact many gene interactions from these two profiles are
significant for these pathways (Figure 6). This is not sur-
prising, since if the expression of one of the genes
involved in the interaction changes dramatically, and the
expression of this gene is much higher than the other
gene, then the sum and higher expression of the two
genes will converge to each other. The competition pro-
file has a strong influence on the identified pathways, as
seen in Figure 2 and 4 (green line represents interactions
detected by competition profile). The reason is not obvi-
ous, and further investigation is needed to reveal it.
It should be noted that the four profiles are related,
for example, the absolute difference equal to the differ-
ence of maximum and minimum profiles. However, the
information on the directionality would be missed if dif-
ference were replaced by absolute difference. To further
investigate the performance of four profiles, we investi-
gated the number of overlapping pathways detected by
two profiles in three breast cancer datasets. The results
Figure 6 Venn diagram of comparison of detected cooperation and redundancy interactions. Pathways detected by both profiles are
similar (Table 1); the comparison of detected interactions also shows high level of similarity.
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http://www.biomedcentral.com/1752-0509/6/65from three datasets are highly similar; table 5 lists the
results from dataset 1 (GSE7390). Overall, three profiles
(cooperation, competition, and dependency) contribute
to the identification of dysregulated pathways in breast
cancer datasets. Although all pathways detected by re-
dundancy profile are identified by other profiles in breast
cancer cases, it did identify one unique pathway in pan-
creatic cancer dataset (Glycosphingolipid biosynthesis,
table 2). Therefore it is useful to consider all four pro-
files to comprehensively identify significantly dysregu-
lated pathways due to the high heterogeneity of cancer
datasets.
Nature of detected interactions
It has been repeatedly shown that human diseases are
associated with perturbations of physical PPIs. In order
to investigate the nature of the dysregulated interactions
identified by GIENA, we compare these interactions
with physical PPIs downloaded from HPRD. The results
show that the overlap between PPI and detected gene
interactions are significant in the p53 dataset: among
215 detected gene interactions in p53 dataset, 23 pairs
also physically interact with each other in a network of
PPIs (p-value< 1.2 × 10-4). In the case of the pancreatic
cancer dataset, 5 out of 173 gene pairs have physical
interaction in HPRD (p-value< 0.13). This observation
suggests that, while a significant number of dysregulated
interactions stem from physical interactions, the natureTable 5 Comparison of performance of four profiles in
dataset 1 (GSE7390) of breast cancer
Cooperation Competition Redundancy Dependency
Cooperation - 5/5 3/5 5/5
Competition 5/8 - 3/8 8/8
Redundancy 3/3 3/3 - 3/3
Dependency 5/10 8/10 3/10 -
The listed are number of overlapping pathways detected by two profiles
divided by the number of pathways detected by the profile in each row. For
other two datasets of breast cancer, the results are similar.of many gene interactions may be indirect and mediated
by other genes, or their interactions are not discovered
by current experiments due to the overall low coverage
of the interactome in HPRD.Conclusions
In summary, GIENA generalizes the gene-based enrich-
ment method to detect pathways that are dysregulated in
diseases based on changes in multiple types of interactions.
Three datasets are used to demonstrate its potential; the
results reveal several well-known and biologically mean-
ingful pathways associated with cancer; and the results are
highly reproducible. Comparison with GSA indicates that
our method is comprehensive and efficient in terms of
extracting weak signals and identifying pathways that are
statistically significant but that a combination of GSA with
GIENA provides the most comprehensive survey of path-
way level dysregulation.
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